Relapsed and/or Refractory Mantle Cell Lymphoma : What Role for Temsirolimus?

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to guide at which place in the current treatment algorithms Temsirolimus can be integrated into the treatment of MCL patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2012

Erschienen:

2012

Enthalten in:

Zur Gesamtaufnahme - volume:6

Enthalten in:

Clinical Medicine Insights. Oncology - 6(2012) vom: 09., Seite 153-64

Sprache:

Englisch

Beteiligte Personen:

Kirschey, Sebastian [VerfasserIn]
Wagner, Susanne [VerfasserIn]
Hess, Georg [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
MTOR-inhibitor
Mantle cell lymphoma
Temsirolimus

Anmerkungen:

Date Completed 23.08.2012

Date Revised 21.10.2021

published: Print-Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.4137/CMO.S7327

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM217451624